Necrobiosis Lipoidica: Treatment and Disease Pathogenesis

The presentation discusses necrobiosis lipoidica (NL), a chronic granulomatous skin disease often associated with diabetes but not limited to diabetic patients. The speaker highlights the clinical features, morphological characteristics, and associated comorbidities of NL, underscoring its tendency to ulcerate and the need for comprehensive patient management. A significant portion of the talk reviews a recent phase two trial investigating the use of topical JAK inhibitors, specifically ruxolitinib, demonstrating promising results in reducing NL scores and improving patients' quality of life. The study included data from around 330 patients, revealing that many had comorbid health issues such as hypertension and autoimmune diseases. Furthermore, there is an association between NL and certain malignancies, prompting careful monitoring and potentially requiring biopsies for non-healing ulcers. The molecular pathogenesis involves upregulation of interferon gamma, which the study suggests could be a target for treatment. The speaker concludes that effective management of NL requires a multidisciplinary approach due to its association with various health issues, alongside the promising role of JAK inhibitors as a therapeutic option.